Email updates

Keep up to date with the latest news and content from AGP and BioMed Central.

Open Access Highly Accessed Primary research

Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry

Icro Maremmani123*, Angelo Giovanni Icro Maremmani12, Fabio Rugani1, Luca Rovai1, Matteo Pacini3, Silvia Bacciardi1, Joseph Deltito34, Liliana Dell’Osso1 and Hagop S Akiskal5

Author Affiliations

1 Vincent P. Dole Dual Diagnosis Unit, Santa Chiara University Hospital, Department of Neurosciences, University of Pisa, Pisa, EU, Italy

2 Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS), Pietrasanta, Lucca, EU, Italy

3 G. De Lisio Institute of Behavioural Sciences, Pisa, EU, Italy

4 Department of Psychiatry and Behavioural Sciences, New York Medical College, Valhalla, NY, USA

5 International Mood Centre, University of California, La Jolla, CA, USA

For all author emails, please log on.

Annals of General Psychiatry 2012, 11:23  doi:10.1186/1744-859X-11-23

Published: 3 September 2012

Abstract

Background

Studies on the ‘self-medication hypothesis’ have focused on substance abuse as an attempt to alleviate emotional suffering.

Methods

We have investigated concomitant substances of abuse in 150 bipolar heroin addicts clustered according to their clinical presentation at treatment entry (depressive episode, hypomanic episode, manic episode and mixed episode). Bipolar heroin addicted patients were chosen because they tend to have a concomitant poly-substance abuse and because, as compared with patients suffering for other mental illnesses, they more clearly reveal a variety of identifiable affective states.

Results

Patients with a depressive episode more frequently used non-prescribed anxiolytic-hypnotics. They were found to use cocaine-amphetamines more frequently during a hypomanic episode, whereas the use of cannabis and cocaine-amphetamines occurred more frequently during a manic episode. The associated use of alcohol, cocaine-amphetamines and cannabinoids was more frequently encountered during a mixed episode. Limitations: apart from the difficulty in determining whether the substance use modifies the mood or the mood state determines the substance used, this is a report on a retrospective analysis, rather than a study specifically designed to elucidate the issue; in addition, no information was available on the temperament of our subjects. Assessments of the same subject in various clinical presentations would have provided a better level of information.

Conclusions

Besides one expected result – the prominent use of CNS stimulants during a depressive phase of bipolar patients – this study supports the hypothesis that mood elation is a pleasurable, rewarding experience that, in bipolar patients, can be started or prolonged by means of CNS stimulant drugs. Stimulant use was, therefore, more prevalent during the ‘up’ rather than the ‘down’ phase of the illness.